Question 1

What is the catalog number for [Nle27]-GRF (1-29) amide (human)?

Accepted Answer

The catalog number for [Nle27]-GRF (1-29) amide (human) is M41197.

Question 2

What sizes are available for [Nle27]-GRF (1-29) amide (human)?

Accepted Answer

[Nle27]-GRF (1-29) amide (human) is available in the following size(s): 100 mg, 25 mg, 50 mg, 500 mg, Inquire.

Question 3

How many pack sizes does [Nle27]-GRF (1-29) amide (human) come in?

Accepted Answer

[Nle27]-GRF (1-29) amide (human) is available in 5 different pack sizes.

Question 4

Is [Nle27]-GRF (1-29) amide (human) in stock?

Accepted Answer

[Nle27]-GRF (1-29) amide (human) is currently made to order / not held in immediate stock. Contact us for lead time.

Question 5

What is [Nle27]-GRF (1-29) amide (human) used for?

Accepted Answer

[Nle27]-GRF (1-29) amide (human)

Question 6

Is this product species cross-reactive?

Accepted Answer

Cross-reactivity data, based on available testing, is listed under the reactivity section of the datasheet. Contact us if you need reactivity confirmed for a species not listed.

Question 7

Is there an additional fee for hazardous or dry ice shipping of this product?

Accepted Answer

Yes, if this product requires dry ice or is classed as hazardous for transport, the additional fee will be explicitly shown in your quotation before you confirm the order, so there are no surprise charges later.

Question 8

How many freeze-thaw cycles can this product tolerate?

Accepted Answer

We recommend aliquoting the product upon receipt to avoid repeated freeze-thaw cycles, which can reduce activity and stability. This is your responsibility once the product has been delivered.

[Nle27]-GRF (1-29) amide (human)

Product Specifications

Stability

Purity

Weight

Molecular Formula

Notes

Receptor

Available Sizes

Frequently Asked Questions

Explore Other Products

Metrnl

Metrnl

Nori Canine SP-D ELISA Kit

VAT1 CRISPRa sgRNA lentivector (set of three targets)(Mouse)

V6 Anti-Human TGFB (Fresolimumab)

V6 Anti-Human TGFB (Fresolimumab)